Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Stage of Development | 8 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Therapy Area | 9 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Indication | 10 | 2 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Companies | 14 | 3 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Products under Development by Universities/Institutes | 17 | 2 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Therapeutics Assessment | 19 | 6 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Companies Involved in Therapeutics Development | 25 | 6 |
| Asana BioSciences, LLC | 25 | 1 |
| Boehringer Ingelheim GmbH | 26 | 1 |
| GlaxoSmithKline Plc | 27 | 1 |
| Takeda Pharmaceutical Company Limited | 28 | 1 |
| Teva Pharmaceutical Industries Ltd. | 29 | 1 |
| Verastem, Inc. | 30 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Drug Profiles | 31 | 25 |
| ASN-006 Drug Profile | 31 | 1 |
| BI-853520 Drug Profile | 32 | 1 |
| CEP-37440 Drug Profile | 33 | 1 |
| cilengitide Drug Profile | 34 | 2 |
| CT-707 Drug Profile | 36 | 1 |
| CTX-0294886 Drug Profile | 37 | 1 |
| CTX-0294945 Drug Profile | 38 | 1 |
| defactinib hydrochloride Drug Profile | 39 | 7 |
| GSK-2256098 Drug Profile | 46 | 2 |
| Small Molecule to Inhibit Focal Adhesion Kinase for Solid Tumors Drug Profile | 48 | 1 |
| Small Molecules to Inhibit FAK for Oncology Drug Profile | 49 | 1 |
| Small Molecules to Inhibit Focal Adhesion Kinase for Oncology Drug Profile | 50 | 1 |
| VS-4718 Drug Profile | 51 | 4 |
| VS-6062 Drug Profile | 55 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Dormant Projects | 56 | 2 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Discontinued Products | 58 | 1 |
| Focal Adhesion Kinase (FAK or EC 2.7.10.2) Featured News &Press Releases | 59 | 12 |
| Jul 05, 2016: Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer | 59 | 1 |
| May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology | 60 | 1 |
| May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016 | 61 | 1 |
| Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology | 61 | 1 |
| Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting | 62 | 1 |
| Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting | 63 | 1 |
| Jan 21, 2016: Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016 | 64 | 1 |
| Jan 06, 2016: Washington University in St. Louis Initiates Clinical Study of Verastem s VS-6063 in Combination with Merck s Pembrolizumab and Gemcitabine in Pancreatic Cancer | 65 | 1 |
| Sep 28, 2015: Verastem Stops Enrollment Due to Futility in the Command Study of Vs-6063 for the Treatment of Malignant Pleural Mesothelioma | 66 | 1 |
| Sep 17, 2015: Verastem Announces Presentation On VS-6063 at ESMO/ECCO 2015 | 66 | 1 |
| Sep 10, 2015: Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer | 67 | 1 |
| Aug 26, 2015: Verastem to Present Data at the 16th World Conference on Lung Cancer | 68 | 1 |
| Dec 11, 2014: Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium | 69 | 1 |
| Dec 04, 2014: Verastem to Present Data on VS-6063 at the 2014 San Antonio Breast Cancer Symposium | 70 | 1 |
| Dec 04, 2014: Verastem to Present Data on VS-4718 at the 2014 San Antonio Breast Cancer Symposium | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |